Aclarion Establishes Commercial Agreement with Weill Cornell Medicine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 08 2026
0mins
Should l Buy ACON?
Aclarion announced it has established a commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center and the multidisciplinary spine team. The trial is entitled "A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate for Osteoarthritis and Degenerative Disc Disease," conducted under IRB Protocol No. 22-06024915. The purpose of this initial study is to investigate whether the dose and quantity of bone marrow aspirate stem cell concentrate used for the treatment of osteoarthritis and/or Degenerative Disc Disease in the spine has an effect on patient-reported functional outcomes and pain. A subset of spine patients will also be eligible for Nociscan.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACON
Wall Street analysts forecast ACON stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.160
Low
23.00
Averages
23.00
High
23.00
Current: 3.160
Low
23.00
Averages
23.00
High
23.00
No data
About ACON
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aclarion Partners with Weill Cornell for Lumbar Surgery Study
- Commercial Agreement Expansion: Aclarion Inc. has established a second commercial agreement with Weill Cornell Medicine to conduct a study on lumbar surgery for degenerative disc disease using its AI-driven platform Nociscan, showcasing the company's ongoing innovation in the healthcare sector.
- Technological Advantage: Nociscan combines artificial intelligence with magnetic resonance imaging to non-invasively identify painful discs in the lumbar spine, achieving a 97% success rate, thus providing an effective treatment option for chronic lower back pain affecting approximately 266 million people globally.
- Clear Research Objectives: The two-year prospective randomized study led by neurosurgeon Roger Hartl aims to deepen the understanding of degenerative disc disease's natural history, causes, and potential treatments, advancing medical knowledge in this area.
- Clinical Application Prospects: The study will evaluate the effectiveness of lumbar microdiscectomy surgery with or without a bone marrow aspirate concentrate injection on patient-reported outcomes, intervertebral disc health, and pain biomarkers, potentially providing crucial data to support future treatment options.
See More
ACLARION SIGNS SECOND COMMERCIAL DEAL WITH WEILL CORNELL MEDICINE
- Announcement of Agreement: Aclarion has announced a second commercial agreement with Weill Cornell Medicine.
- Focus on Collaboration: The agreement aims to enhance collaboration in the field of medical technology and research.
See More
Aclarion Reports 196% Year-over-Year Growth in Nociscan Volumes for Q1 2026
- Significant Volume Growth: Aclarion's Nociscan volumes for Q1 2026 increased by 196% year-over-year compared to Q1 2025, indicating strong market demand and the competitiveness of the company's offerings.
- Quarterly Sequential Improvement: The scan volume also grew by 64% sequentially from Q4 2025 to Q1 2026, demonstrating the company's ability to achieve sustained business expansion and customer growth in the short term.
- Solid Financial Foundation: As of March 31, 2026, Aclarion reported $19 million in cash with no outstanding debt, providing a robust capital structure that supports ongoing growth initiatives.
- Stock Buyback Program: The announcement of a $2.5 million stock buyback program suggests that the company believes its existing cash resources will be sufficient to fund operations into the second half of 2027, thereby enhancing investor confidence and shareholder value.
See More
Aclarion Appoints New Commercial Director to Drive Growth
- Team Expansion: Aclarion has appointed Daniel Keefe as Commercial Director for the Western U.S. to drive the adoption of Nociscan, reflecting a surge in market demand, particularly among academic institutions and high-volume private spine centers, supporting the company's continued growth in this key region.
- Market Performance: Nociscan has seen triple-digit growth in utilization, underscoring its significance in chronic low back pain management, and is expected to further enhance Aclarion's market share and competitiveness in the healthcare technology sector.
- Professional Background: Daniel Keefe brings over 20 years of experience in medical device and technology sales, having held leadership roles at several prominent companies, and his addition is anticipated to provide Aclarion with valuable industry knowledge and market expansion capabilities to bolster business development in the Western U.S.
- Technological Advantage: Nociscan is the first evidence-supported cloud platform that noninvasively helps physicians distinguish between painful and non-painful discs, boasting a 97% surgical success rate when treating Nociscan-positive discs, offering new treatment options for chronic low back pain patients.
See More
Aclarion Announces $2.5 Million Share Repurchase Program
- Repurchase Program Initiation: Aclarion has announced a share repurchase program of up to $2.5 million over the next 12 months, reflecting the company's confidence in its stock value and aiming to enhance shareholder returns.
- Clear Funding Source: The company intends to fund the repurchase using approximately $19.0 million in cash and cash equivalents as of March 31, 2026, ensuring sufficient liquidity and financial stability.
- Positive Market Reaction: Following the announcement, Aclarion's stock price rose by 4.81% in premarket trading, indicating investor optimism regarding the company's future performance.
- Strategic Implications: This repurchase program not only aims to boost earnings per share but may also increase demand for Aclarion's stock in a competitive market, thereby enhancing the company's overall valuation.
See More
Aclarion Authorizes $2.5 Million Share Repurchase Program
- Repurchase Program Initiated: Aclarion, Inc.'s board has authorized a share repurchase program of up to $2.5 million, expected to be executed over the next 12 months, aimed at enhancing shareholder value and boosting market confidence.
- Flexible Value Tool: CEO Brent Ness stated that the program is viewed as a flexible and opportunistic tool to leverage the attractiveness of current share prices while continuing to invest in the clinical adoption and expansion of Nociscan.
- Clear Funding Source: Aclarion intends to fund this repurchase program using existing cash and cash equivalents, ensuring financial stability without compromising other investments.
- Market Reaction Anticipated: The implementation of this repurchase program is expected to enhance investor confidence in Aclarion, potentially having a positive impact on the stock price and further driving the company's growth in the healthcare technology sector.
See More
Aclarion Partners with Weill Cornell for Lumbar Surgery Study
- Commercial Agreement Expansion: Aclarion Inc. has established a second commercial agreement with Weill Cornell Medicine to conduct a study on lumbar surgery for degenerative disc disease using its AI-driven platform Nociscan, showcasing the company's ongoing innovation in the healthcare sector.
- Technological Advantage: Nociscan combines artificial intelligence with magnetic resonance imaging to non-invasively identify painful discs in the lumbar spine, achieving a 97% success rate, thus providing an effective treatment option for chronic lower back pain affecting approximately 266 million people globally.
- Clear Research Objectives: The two-year prospective randomized study led by neurosurgeon Roger Hartl aims to deepen the understanding of degenerative disc disease's natural history, causes, and potential treatments, advancing medical knowledge in this area.
- Clinical Application Prospects: The study will evaluate the effectiveness of lumbar microdiscectomy surgery with or without a bone marrow aspirate concentrate injection on patient-reported outcomes, intervertebral disc health, and pain biomarkers, potentially providing crucial data to support future treatment options.
See More
ACLARION SIGNS SECOND COMMERCIAL DEAL WITH WEILL CORNELL MEDICINE
- Announcement of Agreement: Aclarion has announced a second commercial agreement with Weill Cornell Medicine.
- Focus on Collaboration: The agreement aims to enhance collaboration in the field of medical technology and research.
See More
Aclarion Reports 196% Year-over-Year Growth in Nociscan Volumes for Q1 2026
- Significant Volume Growth: Aclarion's Nociscan volumes for Q1 2026 increased by 196% year-over-year compared to Q1 2025, indicating strong market demand and the competitiveness of the company's offerings.
- Quarterly Sequential Improvement: The scan volume also grew by 64% sequentially from Q4 2025 to Q1 2026, demonstrating the company's ability to achieve sustained business expansion and customer growth in the short term.
- Solid Financial Foundation: As of March 31, 2026, Aclarion reported $19 million in cash with no outstanding debt, providing a robust capital structure that supports ongoing growth initiatives.
- Stock Buyback Program: The announcement of a $2.5 million stock buyback program suggests that the company believes its existing cash resources will be sufficient to fund operations into the second half of 2027, thereby enhancing investor confidence and shareholder value.
See More
Aclarion Appoints New Commercial Director to Drive Growth
- Team Expansion: Aclarion has appointed Daniel Keefe as Commercial Director for the Western U.S. to drive the adoption of Nociscan, reflecting a surge in market demand, particularly among academic institutions and high-volume private spine centers, supporting the company's continued growth in this key region.
- Market Performance: Nociscan has seen triple-digit growth in utilization, underscoring its significance in chronic low back pain management, and is expected to further enhance Aclarion's market share and competitiveness in the healthcare technology sector.
- Professional Background: Daniel Keefe brings over 20 years of experience in medical device and technology sales, having held leadership roles at several prominent companies, and his addition is anticipated to provide Aclarion with valuable industry knowledge and market expansion capabilities to bolster business development in the Western U.S.
- Technological Advantage: Nociscan is the first evidence-supported cloud platform that noninvasively helps physicians distinguish between painful and non-painful discs, boasting a 97% surgical success rate when treating Nociscan-positive discs, offering new treatment options for chronic low back pain patients.
See More
Aclarion Announces $2.5 Million Share Repurchase Program
- Repurchase Program Initiation: Aclarion has announced a share repurchase program of up to $2.5 million over the next 12 months, reflecting the company's confidence in its stock value and aiming to enhance shareholder returns.
- Clear Funding Source: The company intends to fund the repurchase using approximately $19.0 million in cash and cash equivalents as of March 31, 2026, ensuring sufficient liquidity and financial stability.
- Positive Market Reaction: Following the announcement, Aclarion's stock price rose by 4.81% in premarket trading, indicating investor optimism regarding the company's future performance.
- Strategic Implications: This repurchase program not only aims to boost earnings per share but may also increase demand for Aclarion's stock in a competitive market, thereby enhancing the company's overall valuation.
See More
Aclarion Authorizes $2.5 Million Share Repurchase Program
- Repurchase Program Initiated: Aclarion, Inc.'s board has authorized a share repurchase program of up to $2.5 million, expected to be executed over the next 12 months, aimed at enhancing shareholder value and boosting market confidence.
- Flexible Value Tool: CEO Brent Ness stated that the program is viewed as a flexible and opportunistic tool to leverage the attractiveness of current share prices while continuing to invest in the clinical adoption and expansion of Nociscan.
- Clear Funding Source: Aclarion intends to fund this repurchase program using existing cash and cash equivalents, ensuring financial stability without compromising other investments.
- Market Reaction Anticipated: The implementation of this repurchase program is expected to enhance investor confidence in Aclarion, potentially having a positive impact on the stock price and further driving the company's growth in the healthcare technology sector.
See More
